Skip to main content

Table 1 Variables

From: Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease

Demographics
 Gender M/F
 Birthdate dd/mmm/year
 Age at diagnosis years
 Cosanguinity Y/N
 Family history of PD Y/N
 Death date Y/N
 Survival years
Clinical Data
 GD-DS3 mild
moderate
severe
 Spleen removal Y/N
 Liver size cm
 Spleen size cm
 Previous bone crisis Y/N
Image Data
 S-MRI 0-> 9
 DEXA Z score
T score
Analytical Data
 Hemoglobin g/dL
 WBC 109/L
 Platelets 109/L
 B12 vitamin level -serum concentrations, pg/mL
 Iron concentration mg/dL
 Cholesterol mg/dL
 Triglycerides mg/dL
 HDL-cholesterol mg/dL
 LDL-cholesterol mg/dL
 AST/ALT UI
 GGT/ alkaline phosphatase UI
 Bilirrubin mg/dL
 IgG-, IgA-, IgM mg/dL
Diagnosis
 GCase activity nmol/mL/h
GBA genotype NM_000157
Biomarkers
 ChT nmol/mL/h
CHIT1 genotype NM_0003465 Homozygous
Heterozygous
N
 CCL18/PARC ng/mL
 GluSph ng/mL
 Ferritin mcg/L
Follow-up (5-25 y)
 Age to start therapy years
 Type of therapy ERT
SRT
N
 New bone crisis Y/N
 Joint replacement Y/N
 Neoplasia Y/N
 PD Y/N
 Other comorbidities Y/N
  1. S-MRI Spanish magnetic resonance score, DEXA Bone mineral density, GD-DS3 Severity category of GD, WBC white blood cell count, GCase glucocerebrosidase, ChT Chitotriosidase, CCL18/PARC Chemokine ligand 18/Pulmonary and activation-regulated chemokine, GluSph Glucosylsphyngosine, PD Parkinson Disease
\